Terms: = Lymphoma AND CD52, CDW52, EDDM5 AND Diagnosis
20 results:
1. Existing and Emerging Therapies for Cutaneous T-Cell lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract] [Full Text] [Related]
2. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
Loeff FC; Rijs K; van Egmond EHM; Zoutman WH; Qiao X; Kroes WGM; Veld SAJ; Griffioen M; Vermeer MH; Neefjes J; Frederik Falkenburg JH; Halkes CJM; Jedema I
Am J Hematol; 2019 Jan; 94(1):93-102. PubMed ID: 30370942
[TBL] [Abstract] [Full Text] [Related]
3. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg; 2018 Mar; 37(1):2-10. PubMed ID: 29719014
[TBL] [Abstract] [Full Text] [Related]
4. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients.
Vázquez L; Salavert M; Gayoso J; Lizasoaín M; Ruiz Camps I; Di Benedetto N;
Rev Esp Quimioter; 2017 Apr; 30(2):103-117. PubMed ID: 28198173
[TBL] [Abstract] [Full Text] [Related]
5. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract] [Full Text] [Related]
6. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Shao H; Calvo KR; Grönborg M; Tembhare PR; Kreitman RJ; Stetler-Stevenson M; Yuan CM
Leuk Res; 2013 Apr; 37(4):401-409. PubMed ID: 23347903
[TBL] [Abstract] [Full Text] [Related]
7. [Refractory celiac disease].
Vivas Alegre S; Ruiz de Morales JM
Gastroenterol Hepatol; 2008 May; 31(5):310-6. PubMed ID: 18448062
[TBL] [Abstract] [Full Text] [Related]
8. Management of advanced-stage peripheral T-cell lymphomas.
Kimby E
Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
[TBL] [Abstract] [Full Text] [Related]
9. The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms.
Rezania D; Cualing HD; Ayala E
Cancer Control; 2007 Apr; 14(2):151-9. PubMed ID: 17387300
[TBL] [Abstract] [Full Text] [Related]
10. Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.
De Re V; Simula MP; Caggiari L; Orzes N; Spina M; Da ponte A; De Appollonia L; Dolcetti R; Canzonieri V; Cannizzaro R
Clin Exp Immunol; 2007 Jun; 148(3):402-9. PubMed ID: 17335557
[TBL] [Abstract] [Full Text] [Related]
11. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract] [Full Text] [Related]
12. Circulating CD20 and cd52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Keating MJ; Kantarjian HM; Armitage JO; Albitar M
Br J Haematol; 2003 Dec; 123(5):850-7. PubMed ID: 14632776
[TBL] [Abstract] [Full Text] [Related]
13. T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome.
Michallet AS; Lesca G; Radford-Weiss I; Delarue R; Varet B; Buzyn A
Ann Hematol; 2003 Aug; 82(8):515-517. PubMed ID: 12845481
[TBL] [Abstract] [Full Text] [Related]
14. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract] [Full Text] [Related]
15. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract] [Full Text] [Related]
16. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract] [Full Text] [Related]
17. Immunophenotype changes and loss of cd52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
[TBL] [Abstract] [Full Text] [Related]
18. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract] [Full Text] [Related]
19. Chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
[TBL] [Abstract] [Full Text] [Related]
20. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases.
Lockwood CM
J R Coll Physicians Lond; 1998; 32(5):473-8. PubMed ID: 9819743
[TBL] [Abstract] [Full Text] [Related]
